SEN virus infection in patients with chronic hepatitis C: Preferential coinfection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin

Journal of Infectious Diseases

Volumn 187, Issue 2, 2003, Pages 307-310

  Kao, Jia Horng ^a,b   Chen, Wendy ^a   Chen, Pei Jer ^a   Lai, Ming Yang ^a   Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEN VIRUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84984549677     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/346055     Document Type: Article

References (15)

1. Simons JN, Leary TP Dawson GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995; 1:564-9.
2. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997; 241:92-7.
3. Kao JH, Chen PJ, Lai MY, et al. GB virus-C/hepatitis G virus infection in an area endemic for viral hepatitis, chronic liver disease, and liver cancer. Gastroenterology 1997; 112:1265-70.
4. Kao JH, Chen W, Chen PJ, Lai MY, Chen DS. TT virus infection in patients with chronic hepatitis B or C: influence on clinical, histological and virological features. J Med Virol 2000;60: 387-92.
5. Tanaka Y, Primi D, Wang RY, et al. Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. J Infect Dis 2001; 183:359-67.
6. Shibata M, Wang RY, Yoshiba M, Shih JW, Alter HJ, Mitamura K. The presence of a newly identified infectious agent (SEN virus) in patients with liver diseases and in blood donors in Japan. J Infect Dis 2001; 184:400-4.
7. Umemura T, Yeo AE, Sottini A, et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001; 33:1303-11.
8. Kao JH, Chen W, Chen PJ, Lai MY, Chen DS. Prevalence and implication of a newly identified infectious agent (SEN virus) in Taiwan. J Infect Dis 2002; 185:389-92.
9. Rigas B, Hasan I, Rehman R, Donahue P, Wittkowski KM, Lebovics E. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet 2001; 358:1961-2.
10. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-20.
11. Kao JH, Chen PJ, Lai MY, Chen DS. Efficacy of consensus interferon in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2000; 15:1418-23.
12. Umemura T, Alter HJ, Tanaka E, et al. SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology 2002; 35:953-9.
13. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111:1307-12.
14. McHutchinson JG, Gordon S, Schiff ER, et al. Interferon alfa-2b monotherapy versus interferon alfa 2b plus ribavirin as initial treatment for chronic hepatitis C: results of a US multi-center randomized controlled trial. N Engl J Med 1998; 339:1485-92.
15. Kao JH, Chen DS. Recent research progress of hepatocellular carcinoma. J Formos Med Assoc 2002; 101:239-48.